Project Overview +

It's a challenge to know how much it helps to add systemic therapy (e.g., chemotherapy) to a woman's regimen of breast cancer care. For a woman with a favorable prognosis, chemotherapy may add relatively little benefit - but put her through a great deal of difficulty. Genomic testing can help understand who may benefit from chemotherapy and how it impacts the risk of recurrence.

Aims +

Aim 1: Examine patient and physician factors associated with the use of the 21-gene assay.

Aim 2: Examine patient and clinician factors associated with use of chemotherapy and the impact of the assay and its results on use.

Aim 3: Examine the impact of use of the assay on patient knowledge about risk and benefits of chemotherapy and satisfaction with the decision-making process.

Participants +

Participants include 3200 patients with early stage invasive, estrogen receptor-positive breast cancer and their treating oncologist (approximately 270) in state-wide New Jersey and Georgia Surveillance, Epidemiology, and End Results (SEER) registries.

Intervention +

This is a prospective, population-based study; patients who are candidates for the genomic assay and their oncologists are surveyed several months after diagnosis. Patient-reported variables, oncologist knowledge and attitudes elicited through vignettes, practice characteristics from the oncologist survey, and SEER data are merged to create a unique dataset. Multilevel analyses incorporate consideration of patient, clinician, and practice influences on the use of the assay and receipt of chemotherapy.

Individualized CANcer Care (I Can Care): Project 2

07/01/2012 - 06/30/2017


National Cancer Institute

Principal Investigator:

Jennifer J. Griggs, MD, MPH